Entrada Therapeutics announced its third quarter 2026 financial results, highlighting progress in clinical trials for Duchenne muscular dystrophy (DMD). Key data from ELEVATE-44-201 and ELEVATE-45-201 cohorts showed favorable safety and tolerability, with further data expected by year-end 2026 and into 2027. The company holds $193 million in cash, extending its runway into Q4 2027, and anticipates multiple clinical readouts, including a partnership study with Vertex for myotonic dystrophy type 1. These developments mark significant steps toward potential new treatments for serious neuromuscular diseases.
Entrada Therapeutics' third quarter 2026 results provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 05, 2026 18:11 WIB: out of 150 priced US health-sector stocks, 85 rose and 56 fell today. Oscar Health Inc (OSCR) traded at USD 36.25 with a 3.01% gain and a typical hold time of 16 days, contrasting with Maravai LifeSciences Holdings Inc (MRVI) at USD 7.49, which declined 2.98% but showed 100% buy order activity and a shorter hold time of 11 days. Ascendis Pharma A/S (ASND) was priced much higher at USD 250.31, down 2.95%, with the longest typical hold time of 57 days among these.
Scout Clean Energy has announced that its 183 MW Nimbus Wind Farm in Carroll County, Arkansas, is now commercially operational after two years of construction. The wind farm, the largest in Arkansas, generates enough electricity to power over 40,000 ...
CRCAM Toulouse 31 announced the publication and filing of its financial information report for the quarter ending September 30, 2026. The report is accessible to the public on the company's website under the regulatory information section for 2026. T...
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
